Process

Details Process Process

2002-04-01

2004-06-08

Morris, Patricia L. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

06747155

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a novel process for preparing the magnesium salt of the (−)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1
H
-benzimidazole trihydrate, i.e. S-omeprazole magnesium salt trihydrate. The present invention also relates to the S-omeprazole magnesium salt trihydrate prepared in accordance with the novel process and pharmaceutical compositions containing it. Furthermore, the present invention also relates to intermediates used in the process, and their preparation.
BACKGROUND OF THE INVENTION AND PRIOR ART
The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1
H
-benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 5129. The specific alkaline salts of omeprazole are disclosed in EP 124 495. Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for prevention and treatment of gastric-acid related diseases in mammals and especially in man.
Omeprazole is a sulfoxide and a chiral compound, wherein the sulfur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers, the R and S-enantiomer of omeprazole, herein referred to as R-omeprazole and S-omeprazole. The absolute configurations of the enantiomers of omeprazole have been determined by an X-ray study of an N-alkylated derivative of the (+)-enantiomer in non-salt form. The (+)-enantiomer of the non-salt form and the (−)-enantiomer of the non-salt form were found to have R and S configuration, respectively, and the (+)-enantiomer of the magnesium salt and the (−)-enantiomer of the magnesium salt were also found to have R and S configuration, respectively. The conditions for the optical rotation measurement for each of these enantiomers are described in WO 94/27988.
Certain salts of single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988. These compounds have improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation.
WO 96/02535 discloses a process for the preparation of the single enantiomers of omeprazole and salts thereof, and WO 96/01623 discloses a suitable tableted dosage forms of for instance magnesium salts of R- and S-omeprazole.


REFERENCES:
patent: 4255431 (1981-03-01), Junggren et al.
patent: 4738974 (1988-04-01), Brandstrom
patent: 4786505 (1988-11-01), Lovgren et al.
patent: 5530160 (1996-06-01), Nore et al.
patent: 5676884 (1997-10-01), Tiers et al.
patent: 5690960 (1997-11-01), Bengtsson et al.
patent: 5693818 (1997-12-01), von Unge
patent: 5714504 (1998-02-01), Lindberg et al.
patent: 5817338 (1998-10-01), Bergstrand et al.
patent: 5877192 (1999-03-01), Lindberg et al.
patent: 5900424 (1999-05-01), Kallstrom et al.
patent: 1136564 (1996-11-01), None
patent: 0005129 (1979-10-01), None
patent: 0124495 (1984-11-01), None
patent: 0247983 (1987-12-01), None
patent: 9427988 (1994-12-01), None
patent: 9501977 (1995-01-01), None
patent: 9601623 (1996-01-01), None
patent: 9602535 (1996-02-01), None
Erlandsson, P. et al., “Resolution of the enantiomers of omeprazole and some of its analogues by liquid chromatography on a trisphenylcarbamoyl cellulose-based stationary phase”, Journal of Chromatography, 532 (1990) 305-319.
von Unge, S. et al. “Stereochemical assignment of the enantiomers of omerprazole from X-ray analysis of a fenchyloxylmethyl derivative of (+)-(R)-omeprazole”,Tetrahedron Asymmetry, vol. 8, No. 12, pp. 1967-1970 (1997).

Affiliated with

Also associated with

Rating

Process does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3310856